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While p21 is a member of the cip/kip family of cyclin kinase
“inhibitors,” it possesses a variety of properties that make this
appellation, in many ways, a confusing misnomer. The initial
descriptions of p21 focused on its location in the tumor suppres-
sor pathway downstream of p53 (el-Deiry et al., 1993), its func-
tion as an inhibitor of G1 cyclin kinases (Xiong et al., 1993;
Harper et al., 1993), and its role in differentiation (Sherr and
Roberts, 1999). However, more recent investigations have
shown that p21 also plays roles in allowing cell cycle transit as
well as preventing apoptosis; since programmed cell death is
the ultimate mechanism by which cancer chemotherapeutics
exert their salutary effects on tumor cells, this property of p21
has considerable untapped potential to be of fundamental
importance in the therapy of human cancer.
p21 and the cell cycle
Sequential activation of cyclin/CDK pairs regulates progression of
cells through the cell cycle. Due to its placement in the p53 signal-
ing cascade downstream of this all-important tumor suppressor,
the initial descriptions of p21 focused on its ability to complex with
cyclin A/CDK2 and cyclin D1/CDK4 pairs (on separate binding
sites of the p21 protein) and inhibit their activity in vitro. However,
the story became more complicated when it was found that
p21/cyclin A/CDK2 complexes exist in both catalytically active and
inactive forms (Zhang et al., 1994), suggesting that perhaps it was
a stoichiometry issue related to the number of molecules of p21
relative to the cyclin/CDK complex which dictated the ultimate
response of a cell to p21. This mechanistic possibility was called
into question by later work, based on the crystal structure showing
that a single p21 molecule can bind to both cyclin and CDK sub-
units, demonstrating substantial cyclin A/CDK2 inhibition at a
mere 1:1 molar ratio of p21 to the cyclin A/CDK2 complex (Hengst
et al., 1998; Adkins and Lumb, 2000). In addition to the cyclin and
CDK binding sites on p21, there exists a distinct PCNA binding
site on p21, raising the possibility that sequestration of PCNA,
which is required for DNA polymerase δ function, could be a
mechanism by which p21 attenuates cell growth (Rossig et al.,
2001). This possibility was supported by data showing that the
PCNA interaction with p21 increases the latter protein’s stability
(Cayrol and Ducommun, 1998).
Regardless of the stoichiometry and PCNA binding argu-
ments, and based on the previously mentioned finding that
p21/cyclin/CDKs can exist in active complexes, more recent
work in our and other laboratories has led to the discovery that
p21 is required for G1→S phase progression in at least some
cell types. The role for p21 as an assembly factor for cyclin
D1/CDK4 complexes (Weiss et al., 2000; LaBaer et al., 1997)
helps explain the heretofore mysterious result that p21 levels
are increased soon after mitogen stimulation. Data is emerging
showing that, in addition to its growth inhibitory role, p21 can
function in a positive fashion toward cell proliferation (Dong et
al., 2003; Dupont et al., 2003; Zhang et al., 2003), a finding, of
course, with practical relevance toward cancer therapy. In retro-
spect, this finding was not altogether unexpected based on a
growing body of evidence for p21 as a target for PI3K through
Akt-induced phosphorylation, since PI3K itself possesses cell
cycle progression properties (in addition to its effect on apopto-
sis—see below). It now appears that the switch between cell
cycle promotion and inhibition by p21 may occur by virtue of the
subcellular localization of this protein, as cytosolic localization
of p21, using a mutant that mimics phosphorylation on threo-
nine 145, resulted in a loss of the cell cycle inhibitor property of
p21 (Zhou et al., 2001). In addition, the forced cytosolic localiza-
tion of p21 using an NLS-deficient construct resulted in cell
cycle progression (Dong et al., 2003) as well as protection from
apoptosis (Asada et al., 1999). In other related studies, p21 has
been shown to mediate the pro-proliferative effect of IGF-1
(Dupont et al., 2003) and Ets-1 (Zhang et al., 2003) in a variety
of cells. However, p21 also appears to play a positive role in cel-
lular senescence, at least in HeLa cells, as its overexpression in
these cells induces this phenotype while attenuation inhibits
senescence (Wells et al., 2000; Goodwin and DiMaio, 2000).
Furthermore, microinjection of anti-p21 antibody into senescent
Hs68 human foreskin fibroblasts resulted in their reentry into
the cell cycle (Ma et al., 1999).
After all is said and done, however, and despite these
advances in knowledge of the molecular biology of p21, the pre-
cise mechanism by which this multifunctional protein regulates
cell cycle progression remains, for the moment at least,
unknown.
p21 and apoptosis
Cells with damaged DNA and consequent increased p53 acti-
vation can either have their DNA repaired or, if the damage is so
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extensive that this is not possible, the cells will be sent to the
apoptotic garbage heap, thereby preserving genomic integrity
(Figure 1). The function of p21 to arrest growth after DNA dam-
age (in response to activated p53) has been well established,
yet recently a critical role of p21 to concomitantly prevent apop-
tosis has been uncovered. This sequence of events makes tele-
ological sense because a repairing cell requires time; a dead
cell with its DNA repaired is a waste of cellular energy.
In response to DNA damage and subsequent p53 activation,
the cell has to make a decision between cell cycle arrest and
apoptosis. In an important study addressing the mechanism of
this phenomenon, Massague’s group demonstrated a critical role
of Myc and the DNA binding protein Miz-1, being recruited to the
p21 promoter and influencing the outcome of the p53 response to
DNA damage (Seoane et al., 2002). Another key mechanistic
study showed that caspase-3 mediated cleavage of p21 during
the apoptotic process sends growth-arrested cells to apoptosis
(Zhang et al., 1999)
Phosphorylation of p21 by Akt, which lies downstream of the
antiapoptotic signaling protein PI3K, resulted in increased p21
stability as well as enhanced glioblastoma cell survival (Li et al.,
2001). Constitutively activated Akt, which lies downstream of the
antiapoptotic signaling protein PI3K, results in cytosolic localiza-
tion of p21 and suppression of its growth-inhibiting activity (Zhou
et al., 2001). The latter study also suggested that cytosolic p21
may increase cell proliferation in Her-2/neu overexpressing cells.
Paclitaxel was found to cause cytosolic localization of p21, result-
ing in attenuation of its antiproliferative effect in squamous carci-
noma RPMI-2650 cells (Heliez et al., 2003). p21 also becomes
localized to the cytoplasm during differentiation of at least some
cell types (Asada et al., 1999; Tanaka et al., 2002); this localiza-
tion allows p21 to act upon targets molecules such as SAP (Shim
et al., 1996) and ASK1 (Asada et al., 1999) kinases to inhibit their
catalytic activities and thus prevent apoptosis.These data further
suggest that subcellular localization is not only important for the
antiapoptotic effect, but may be key to promoting cell proliferation,
consistent with the cell cycle progression activity seen in vascular
smooth muscle (VSM) cells with forced increased cytosolic p21
(Dong et al., 2003).Thus, p21 is not only a cell cycle inhibitor and
cyclin/CDK assembly factor, but it also functions as an antiapo-
ptotic and growth-promoting protein; the latter properties suggest
that, at least in some contexts, this protein may be eminently
exploitable in cancer.
p21 and cancer
The cancer community has been somewhat slow to embrace
the possibility of using the CKIs as cancer targets, which is
understandable considering the original press on this protein
showing that (1) it lies downstream of the all-important guardian
of the genome, p53, which, of course, is not to be tampered
with; and (2) it is a “universal inhibitor” of cyclin kinases (Xiong
et al., 1993). However, in light of the recent data described
above that p21 also functions, under the appropriate conditions,
as an antiapoptotic and growth-enhancing protein, its potential
use in cancer needs to be revisited.
The reason that cancer is a relatively rare disease in
humans, considering the number of cell divisions taking place,
is that the organism has evolved an exquisite mechanism for
ridding the body of genetically damaged cells such that they do
not acquire neoplastic autonomy. These events are in large part
due to p53 and its relatives, such that loss of function of this pro-
tein is indeed cataclysmic. On the other hand, many cancer
cells with deregulated oncogenes are in fact treading on thin
ice, as they appear to be highly sensitive to apoptosis. This
property has not escaped the notice of clinical oncologists,
since much of the chemotherapeutic armamentarium is
designed to terminally damage DNA of cancer cells, such that
p53-mediated repair is impossible.
The bane of cancer chemotherapy is its narrow therapeutic
window: too low a dose will lead to complete cell repair and no
effect, too high will lead to death of more cells (including non-
cancerous ones) than the organism can bear. Thus, any “sensi-
tizer” that might force cells with even mild DNA damage into an
apoptotic program would have the potential to greatly enhance
the efficacy, and thereby limit toxic side effects, of DNA-damag-
ing chemotherapeutic agents. Enter p21: the executor of p53’s
antiapoptotic agenda.
Consistent with the previously discussed finding that p21 is
increased early after mitogen stimulation, it has been found that
overexpression of p21 is an early event in the development of at
least some neoplasms (Biankin et al., 2001). Could these find-
ings be related? It has also been shown that p21 is required for
the effective coordination between S phase and mitosis, and,
utilizing p21(−/−) cells, these investigators demonstrated an
enhanced apoptotic effect of chemotherapeutic agents and γ
irradiation, as compared to p21(+/+) colorectal cancer cells
(Waldman et al., 1996). Subsequently, using a xenograft model,
it was found that p21-deficient tumors were more sensitive to
radiation as measured by both clonogenic survival and regrowth
of the tumors following treatment (Wouters et al., 1997). p21-
disrupted clones of HCT-116 colon cancer cells were found to
have higher sensitivity to cisplatin and nitrogen mustard (Fan et
al., 1997). Furthermore, paclitaxel increases p21 and causes it
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Figure 1. p21 determines the fate of DNA-damaged cells
Upon detection of as little as a single strand break, the p53 pathway is acti-
vated, leading to either apoptosis (through activation of such genes as
PUMA and PIG3) or antiapoptosis (through p21 mediated by Myc and the
DNA binding protein Miz-1). The subsequent increase in p21 allows the cell
to survive the DNA repair process.
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to relocate in the cytoplasm where, as discussed above, it is
antiapoptotic and causes less cell cycle inhibition (Heliez et al.,
2003). Consistent with this data, cytosolic p21 is indeed associ-
ated with a poorer prognosis, as assessed by decreased overall
as well as relapse-free survival, in breast cancer (Winters et al.,
2003). These findings suggest the possibility that attenuating
expression or stability of p21 may be useful as possible
chemotherapy, as will be discussed below.
Therapeutic possibilities of p21 manipulation in cancer
Although much of the original experimental work has been done
in p21 knockout cells, the stage has now clearly been set for
attempting to attenuate p21 levels in cancer cells. Theoretically,
this may ultimately be clinically useful in conjunction with DNA-
damaging chemotherapeutic agents (Figure 2). The search for
specific pharmaceutical agents to attenuate p21 has not yielded
many players, in part because p21 attenuation has not, as yet,
been intensively studied for this purpose. In general, as dis-
cussed above, standard DNA damaging chemotherapeutic
agents, such as Adriamycin, increase p21 through p53-depen-
dent and -independent pathways; these mechanisms serve the
cancer cell quite well and protect these malignant cells from
apoptosis (Bunz et al., 1999), an event which does not help the
patient. On the other hand, triptolide, an immunosuppressive
extract of the Chinese herb Tripterygium wilfordii, shows some
promise, as it causes apoptosis by induction of p53 with con-
comitant inhibition of p21 expression (Chang et al., 2001). The
use of peptides or small molecule inhibitors (Lam et al., 2003) to
attenuate p21, or to modulate its interaction with antiapoptotic
partner proteins such as Akt, has enormous potential but has
not yet been described in this regard.
Thus far, the most widely reported method for attenuation of
p21 which has potential clinical applicability has been the use of
antisense techniques, either by transfection of an antisense
oligodeoxynucleotide (ODN) or by utilizing antisense plasmid
technology. We showed that transfection of a 21 bp antisense
p21 ODN results in attenuation of rat VSM cell growth (Weiss et
al., 2000), and another group showed that this same ODN
induced apoptosis in other VSM cell lines (Zhang et al., 2003). A
human ODN, homologous to the rat one above, promoted apop-
tosis in both T47D and MCF7 human breast cancer cell lines
(Fan et al., 2003), and a different antisense p21 ODN caused
irradiated HCT116 human colon cancer cells to convert from
growth arrest to apoptosis (Tian et al., 2000). Stable transfec-
tants of antisense p21 encoded plasmids resulted in sensitiza-
tion of BCap37 human breast cancer cells to paclitaxel and its
combination with 5-fluorouacil (Johnson and Fan, 2002); this
latter study is of particular interest, since it seems that one
mechanism by which cancer cells might resist paclitaxel therapy
is through escape from apoptosis by means of an increase in
p21 synthesis after exposure to this agent (Heliez et al., 2003).
Antisense ODNs to p21 also enhanced γ irradiation-induced
apoptosis and cytotoxicity in radioresistant human glioma cells
(Kokunai et al., 2001). We showed in a pilot study of an allograft
model of breast cancer that antisense p21 ODN, when injected
subcutaneously in nude mice, results in attenuation of Met-1
breast cancer growth (Weiss et al., 2003). The few reported
studies using siRNA to suppress expression of p21 (in two spe-
cialized cell lines) resulted in inhibition of apoptosis in insulin-
secreting cells (Huo et al., 2003), and restoration of
immortalization as well as Ras-mediated transformation in cdk4
null cells (Zou et al., 2002).The difference in outcomes between
these two techniques of p21 attenuation may be due to the
magnitude and/or duration of its suppression, and requires fur-
ther study.
In breast cancer, both increased cytosolic p21 (Winters et
al., 2003) and higher (total) p21 expression by immunostaining
(Yang et al., 2003) have been linked to poorer prognosis. In the
latter study, patients treated with CMF who had positive p21
expression in their tumors had significantly worse disease-free
survival than those whose tumors stained negative for p21.
Although both studies involved breast cancer patients, in con-
trast to Winters et al., Yang et al. showed a marginally signifi-
cant (p = 0.05) association of nuclear p21 with worse
disease-free survival, and no similar association with cytosolic
localization; the difference between these studies may be due
to the fact that all of the patients studied by Yang et al. had
already received CMF, while the patients in Winters et al.
received a variety of adjuvant treatments or none at all. The
finding by Yang et al. that ErbB2 overexpression correlated sig-
nificantly with p21 positivity in these patients suggests that an
immune-mediated approach, utilizing already available tumor-
targeting anti-HER2 monoclonal antibodies and concomitant
specific p21-attenuating therapy (as with immunoliposomes
carrying antisense ODNs [Park et al., 2002; Rodriguez et al.,
2002]), may ultimately be feasible. In addition, staining of
breast tumors for p21 or cytosolic-localized p21 may prove
useful in stratifying patients who may respond to such p21-
attenuating therapy.
While antisense techniques show promise and have been
available for some time, their movement into the clinical arena is
still under investigation; based on the studies described above,
antisense p21 ODN or gene therapy to attenuate p21 levels in
tumors and/or patients has tremendous potential as therapy,
likely in combination with standard DNA-damaging agents.
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Figure 2. A scenario for the use of p21 attenuators to enhance chemother-
apeutic efficacy
Depending on the severity of DNA damage, response to a chemothera-
peutic agent will be either apoptosis (an effective drug) or successful
repair (drug resistance). Based on the current knowledge of p21 as an anti-
apoptotic protein, it is conceivable that transient attenuation of p21 con-
comitant with DNA damaging chemotherapy, such as with antisense
techniques or small molecule inhibitors (purple shading), would improve
the efficacy, and thus decrease toxicity, of standard chemotherapeutic
agents.
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p21 levels and mutations in cancer: A caution
While in general, p21 mutations are rare in cancer, there are scat-
tered reports of mutations in several cancer types, such as oral
(Ralhan et al., 2000), esophageal (Bahl et al., 2000), and breast
(Balbin et al., 1996). A close examination of the several polymor-
phisms which have been identified in p21 in human breast cancer
in small studies (Powell et al., 2002; Keshava et al., 2002) reveals
one (described only in thyroid carcinomas [Shi et al., 1996]) which
lies in intron 2 between exons 2 and 3, which is spliced out to cre-
ate the NLS sequence and is therefore a possible site for onco-
genic mutations; patients with this mutation had a slightly higher
breast cancer risk. The only exon polymorphism described in the
p21 NLS and PCNA binding region is in codon 149. Another
report describes a mutation in one tumor (out of 36 screened)
which does not lie in the PCNA binding region and yet impairs the
ability of p21 to inhibit proliferation (Balbin et al., 1996). While
cytosolic localization of p21 is associated with a poorer prognosis
in breast cancer (Winters et al., 2003), a finding which might in
the future be able to identify patients who would respond to p21
attenuating therapy, studies correlating levels of p21 with progno-
sis and tumor grade have been inconsistent.
Surprisingly, in light of its location downstream of p53 in the
tumor suppressor pathway, p21(−/−) mice showed normal
development and did not show spontaneous tumor develop-
ment at 7 months in the original study (Deng et al., 1995), yet
embryonic fibroblasts were deficient in their ability to arrest in
response to DNA damage. In addition, p21(−/−) thymocytes
showed a dramatic increase in cells undergoing apoptosis
(Deng et al., 1995), and p21(−/−) keratinocytes showed an
increased proliferation potential (Missero et al., 1996). A later
study showed that p21(−/−) mice, when followed longer, showed
an increase in spontaneous tumor development at an average
age of 16 months, whereas wild-type mice are typically tumor-
free beyond 2 years (Martin-Caballero et al., 2001).
Furthermore, disruption of the p21 gene in mice led to a
increased susceptibility to chemically induced skin carcinoma
formation (Topley et al., 1999), and p21 null mice had accelerat-
ed tumor onset and multiplicity in urethane-treated animals,
although this mutation had no effect on tumor growth rate in v-
Ha-ras mice (Jackson et al., 2002). While these studies should
inject a note of caution into translational p21 attenuation pur-
suits, it is necessary to keep in mind that (1) future therapies
employing p21 attenuation will likely focus on the proapoptotic
(rather than growth-regulatory) properties of these techniques,
and (2) effective p21-attenuative therapies will result in transient
and partial attenuation, in contradistinction to constitutive
absence of this gene as is seen in knockout models.
Future directions
Due to the unacceptable failure rate of currently available cancer
chemotherapeutics, the search for new molecular targets is in
high gear. While initially touted (and investigated) as an inhibitor
of cell growth, p21 has now emerged as a powerful antiapoptotic
signaler under some conditions. Since many cancer cells are
able to escape a chemotherapeutic death by repairing their dam-
aged DNA by means of p21 augmentation, methods of transient-
ly attenuating p21 in combination with standard DNA-damaging
pharmaceuticals hold considerable promise to limit chemothera-
py toxicity and improve patient outcomes. Future work in this
area should focus on, among other methods, antisense and
small molecule inhibitor techniques to transiently inhibit p21 in
animal studies and subsequently in clinical trials.
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